Just Block This Right Here, Thanks

genomeweb
360dx

Just Block This Right Here, Thanks

Dec 05, 2009

A hepatitis C drug from Santaris targeting a microRNA is now in the early stages of clinical testing, reports Technology Review. The drug, a synthetic nucleic acid, binds miR-122, which the hepatitis C virus needs to reproduce.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

Checkpoint Immunotherapy Response Described in Tumors with Gene Fusion-Based Neoantigens
Top Five Articles on GenomeWeb Last Week: UK Investigating Illumina-PacBio Deal; Inova Ends PGx Test
Active Celiac Disease Processes Informed by Intestinal Expression Comparison
American Cancer Society Philanthropic Fund BrightEdge Invests in Castle Bio
PetaGene Inks Reseller Agreement With NetApp
Genetic Obesity Risk From Polygenic Score May Help With Disease Prevention

The Scan

Pushed Aside

The New York Times Magazine examines gender discrimination at the Salk Institute.

Dismissals at MD Anderson

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

Looking Into It

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

This Week in PLOS

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.

Menu